Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409732 · ClinicalTrials.gov registry record · Phase 4
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT02409732: Completed Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
NCT02409732 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02409732, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of PDT with blue light and topical Levulan in the treatment of actinic cheilitis.
Primary Outcome
Clearance will be estimated clinically as minimal (0%-25%), mild (26%-50%), moderate (51%-75%), good (76%-99%), or complete (100%). Results will also be evaluated by comparing photographs before and immediately after treatments, and 12 and 24 weeks after the last treatment.
Interventions
- DRUG aminolevulinic acid hydrochloride
- PROCEDURE Photodynamic therapy with blue light
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
What the finished NCT02409732 record still lists
NCT02409732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which aminolevulinic acid hydrochloride is the first listed.
NCT02409732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02409732 about?
NCT02409732 is a clinical study titled "Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis". To evaluate the safety and efficacy of PDT with blue light and topical Levulan in the treatment of actinic cheilitis.
What is the current status of trial NCT02409732?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2015-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02409732?
The interventions under investigation include: aminolevulinic acid hydrochloride (DRUG), Photodynamic therapy with blue light (PROCEDURE).
Who is sponsoring clinical trial NCT02409732?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02409732's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia